-
Je něco špatně v tomto záznamu ?
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide
S. Kayser, J. Krzykalla, MA. Elliott, K. Norsworthy, P. Gonzales, RK. Hills, MR. Baer, Z. Ráčil, J. Mayer, J. Novak, P. Žák, T. Szotkowski, D. Grimwade, NH. Russell, RB. Walter, EH. Estey, J. Westermann, M. Görner, A. Benner, A. Krämer, BD....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
NV15-25809A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 1997-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-02-01 do 2017-12-31
PubMed
28322237
DOI
10.1038/leu.2017.92
Knihovny.cz E-zdroje
- MeSH
- akutní promyelocytární leukemie farmakoterapie etiologie genetika MeSH
- analýza přežití MeSH
- arsenikové přípravky terapeutické užití MeSH
- dospělí MeSH
- indukce remise MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- oxidy terapeutické užití MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- sekundární malignity farmakoterapie etiologie genetika MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated 103 adult t-APL patients undergoing treatment with all-trans retinoic acid (ATRA) alone (n=7) or in combination with ATO (n=24), CTX (n=53), or both (n=19). Complete remissions were achieved after induction therapy in 57% with ATRA, 100% with ATO/ATRA, 78% with CTX/ATRA, and 95% with CTX/ATO/ATRA. Early death rates were 43% for ATRA, 0% for ATO/ATRA, 12% for CTX/ATRA and 5% for CTX/ATO/ATRA. Three patients relapsed, two developed therapy-related acute myeloid leukemia and 13 died in remission including seven patients with recurrence of the prior malignancy. Median follow-up for survival was 3.7 years. None of the patients treated with ATRA alone survived beyond one year. Event-free survival was significantly higher after ATO-based therapy (95%, 95% CI, 82-99%) as compared to CTX/ATRA (78%, 95% CI, 64-87%; P=0.042), if deaths due to recurrence of the prior malignancy were censored. The estimated 2-year overall survival in intensively treated patients was 88% (95% CI, 80-93%) without difference according to treatment (P=0.47). ATO when added to ATRA or CTX/ATRA is feasible and leads to better outcomes as compared to CTX/ATRA in t-APL.
Cardiff University School of Medicine Cardiff UK
Department of Haematology Nottingham University Hospitals NHS Trust Nottingham UK
Department of Internal Medicine 1 University Hospital Carl Gustav Carus Dresden Germany
Department of Internal Medicine 5 University Hospital of Heidelberg Heidelberg Germany
Division of Biostatistics German Cancer Research Center Heidelberg Germany
Division of Hematology Department of Internal Medicine Mayo Clinic Rochester Minnesota USA
Klinik für Hämatologie Onkologie und Palliativmedizin Klinikum Bielefeld Mitte Bielefeld Germany
National Center for Tumor Diseases Heidelberg University Hospital Heidelberg Germany
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore Maryland USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016714
- 003
- CZ-PrNML
- 005
- 20201015140156.0
- 007
- ta
- 008
- 180515s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/leu.2017.92 $2 doi
- 035 __
- $a (PubMed)28322237
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kayser, S $u Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany. Department of Internal Medicine V, Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), University of Heidelberg, Heidelberg, Germany.
- 245 10
- $a Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide / $c S. Kayser, J. Krzykalla, MA. Elliott, K. Norsworthy, P. Gonzales, RK. Hills, MR. Baer, Z. Ráčil, J. Mayer, J. Novak, P. Žák, T. Szotkowski, D. Grimwade, NH. Russell, RB. Walter, EH. Estey, J. Westermann, M. Görner, A. Benner, A. Krämer, BD. Smith, AK. Burnett, C. Thiede, C. Röllig, AD. Ho, G. Ehninger, RF. Schlenk, MS. Tallman, MJ. Levis, U. Platzbecker,
- 520 9_
- $a Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated 103 adult t-APL patients undergoing treatment with all-trans retinoic acid (ATRA) alone (n=7) or in combination with ATO (n=24), CTX (n=53), or both (n=19). Complete remissions were achieved after induction therapy in 57% with ATRA, 100% with ATO/ATRA, 78% with CTX/ATRA, and 95% with CTX/ATO/ATRA. Early death rates were 43% for ATRA, 0% for ATO/ATRA, 12% for CTX/ATRA and 5% for CTX/ATO/ATRA. Three patients relapsed, two developed therapy-related acute myeloid leukemia and 13 died in remission including seven patients with recurrence of the prior malignancy. Median follow-up for survival was 3.7 years. None of the patients treated with ATRA alone survived beyond one year. Event-free survival was significantly higher after ATO-based therapy (95%, 95% CI, 82-99%) as compared to CTX/ATRA (78%, 95% CI, 64-87%; P=0.042), if deaths due to recurrence of the prior malignancy were censored. The estimated 2-year overall survival in intensively treated patients was 88% (95% CI, 80-93%) without difference according to treatment (P=0.47). ATO when added to ATRA or CTX/ATRA is feasible and leads to better outcomes as compared to CTX/ATRA in t-APL.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a arsenikové přípravky $x terapeutické užití $7 D001152
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a akutní promyelocytární leukemie $x farmakoterapie $x etiologie $x genetika $7 D015473
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a sekundární malignity $x farmakoterapie $x etiologie $x genetika $7 D016609
- 650 _2
- $a oxidy $x terapeutické užití $7 D010087
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Krzykalla, J $u Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
- 700 1_
- $a Elliott, M A $u Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- 700 1_
- $a Norsworthy, K $u Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
- 700 1_
- $a Gonzales, P $u Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
- 700 1_
- $a Hills, R K $u Cardiff University School of Medicine, Cardiff, UK.
- 700 1_
- $a Baer, M R $u University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA. Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
- 700 1_
- $a Ráčil, Z $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Mayer, J $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Novak, J $u 3rd Faculty of Medicine, Department of Internal Medicine and Haematology, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
- 700 1_
- $a Žák, P $u Faculty of Medicine, 4th Department of Internal Medicine-Hematology, Charles University and University Hospital Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Szotkowski, T $u Faculty of Medicine and Dentistry, Department of Hemato-Oncology, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Grimwade, D $u Faculty of Life Sciences and Medicine, Department of Medical & Molecular Genetics, King's College London, London, UK.
- 700 1_
- $a Russell, N H $u Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
- 700 1_
- $a Walter, R B $u Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA. Department of Epidemiology, University of Washington, Seattle, WA, USA.
- 700 1_
- $a Estey, E H $u Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA.
- 700 1_
- $a Westermann, J $u Department of Hematology, Oncology and Tumor Immunology, Charité-University Medical Center, Campus Virchow Clinic, Berlin, Germany.
- 700 1_
- $a Görner, M $u Klinik für Hämatologie, Onkologie und Palliativmedizin, Klinikum Bielefeld Mitte, Bielefeld, Germany.
- 700 1_
- $a Benner, A $u Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
- 700 1_
- $a Krämer, A $u Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany. Department of Internal Medicine V, Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), University of Heidelberg, Heidelberg, Germany.
- 700 1_
- $a Smith, B D $u Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
- 700 1_
- $a Burnett, A K $u Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
- 700 1_
- $a Thiede, C $u Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany.
- 700 1_
- $a Röllig, C $u Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany.
- 700 1_
- $a Ho, Anthony, $d 1948- $7 xx0250201 $u Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.
- 700 1_
- $a Ehninger, G $u Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany.
- 700 1_
- $a Schlenk, R F $u National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
- 700 1_
- $a Tallman, M S $u Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
- 700 1_
- $a Levis, M J $u Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
- 700 1_
- $a Platzbecker, U $u Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 31, č. 11 (2017), s. 2347-2354
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28322237 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20201015140153 $b ABA008
- 999 __
- $a ok $b bmc $g 1300338 $s 1013554
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 31 $c 11 $d 2347-2354 $e 20170321 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- GRA __
- $a NV15-25809A $p MZ0
- LZP __
- $a Pubmed-20180515
